Ownership Submission

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

ROSENWALD LINDSAY A MD

2. Issuer Name and Ticker or Trading Symbol
CORONADO BIOSCIENCES INC [CNDO]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

__X__ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

(Last)

(First)

(Middle)

C/O CORONADO BIOSCIENCES, INC., 24 NEW ENGLAND EXECUTIVE PARK

3. Date of Earliest Transaction (Month/Day/Year)
10/25/2011

(Street)

BURLINGTON, MA 01803

4. If Amendment, Date Original Filed(Month/Day/Year)
02/14/2012

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security
(Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code
(Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date
(Month/Day/Year)

7. Title and Amount of Underlying Securities
(Instr. 3 and 4)

8. Price of Derivative Security
(Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)

11. Nature of Indirect Beneficial Ownership
(Instr. 4)

Code

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Warrants to purchase Common Stock

$ 6.15 ⁽¹⁾

10/25/2011⁽¹⁾

6,798 ⁽¹⁾

⁽²⁾

⁽¹⁾⁽³⁾

Common Stock

6,798 ⁽¹⁾

$ 0

6,798 ⁽¹⁾

By LAR Family Trusts

Warrants to purchase Common Stock

$ 6.15 ⁽⁴⁾

10/25/2011⁽⁴⁾

3,399 ⁽⁴⁾

⁽²⁾

⁽⁴⁾⁽⁵⁾

Common Stock

3,399 ⁽⁴⁾

$ 0

3,399 ⁽⁴⁾

By LAR Family Trusts

Warrants to purchase Common Stock

$ 6.15 ⁽⁶⁾

10/25/2011⁽⁶⁾

850 ⁽⁶⁾

⁽²⁾

⁽⁶⁾⁽⁷⁾

Common Stock

850 ⁽⁶⁾

$ 0

850 ⁽⁶⁾

By LAR Family Trusts

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
ROSENWALD LINDSAY A MD C/O CORONADO BIOSCIENCES, INC. 24 NEW ENGLAND EXECUTIVE PARK BURLINGTON, MA 01803	X	X

Signatures

/s/ Dale Ritter, Attorney-in-Fact		02/13/2013
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This warrant was previously reported on February 14, 2012 with an incorrect exercise price of $9.23, transaction date of January 22, 2009, reference to 4,529 derivative securities acquired and beneficially owned and expiration date of January 22, 2014.
(2)	This warrant is fully vested.
(3)	4,472 shares underlying this warrant expire on January 22, 2014, 835 shares underlying this warrant expire on May 28, 2014 and 1,491 shares underlying this warrant expire on June 24, 2014.
(4)	This warrant was previously reported on February 14, 2012 with an incorrect exercise price of $9.23, transaction date of May 28, 2009, reference to 2,265 derivative securities acquired and beneficially owned and expiration date of May 28, 2014.
(5)	2,236 shares underlying this warrant expire on January 22, 2014, 417 shares underlying this warrant expire on May 28, 2014 and 746 shares underlying this warrant expire on June 24, 2014.
(6)	This warrant was previously reported on February 14, 2012 with an incorrect exercise price of $9.23, transaction date of June 24, 2009, reference to 566 derivative securities acquired and beneficially owned and expiration date of June 24, 2014.
(7)	559 shares underlying this warrant expire on January 22, 2014, 104 shares underlying this warrant expire on May 28, 2014 and 187 shares underlying this warrant expire on June 24, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.